Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Hemostatic material based on combination of chitosan and tissue factor, and preparation method thereof

A technology of tissue factor and hemostatic materials, applied in surgical adhesives, applications, medical science, etc., can solve problems affecting wound healing, limited hemostatic effect, skin burns, etc., and achieve good hemostatic effect, stable and rapid hemostatic effect, and hemostasis time short effect

Active Publication Date: 2020-10-02
BEIJING REDCUBE MEDICAL EQUIP +1
View PDF5 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Among the hemostatic materials commonly used in the market today, such as gelatin, which is non-antigenic and easy to absorb, quickly absorbs water and swells to activate platelets and form blood clots, but there are problems of animal origin and tissue inflammation; zeolite can quickly absorb water and increase the concentration of coagulation factors , to promote blood coagulation, but due to absorbing water and releasing a lot of heat, the local temperature of the wound will exceed 90 degrees Celsius, causing skin burns and affecting wound healing; as a new generation of hemostatic drug, chitosan has good biocompatibility and can be biodegraded. No rejection, its molecules directly gather platelets and red blood cells on the wound surface to promote blood coagulation, but the hemostatic effect of chitosan alone is still limited

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Hemostatic material based on combination of chitosan and tissue factor, and preparation method thereof
  • Hemostatic material based on combination of chitosan and tissue factor, and preparation method thereof
  • Hemostatic material based on combination of chitosan and tissue factor, and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0024] Embodiment 1: a kind of preparation method based on chitosan and tissue factor combined hemostatic material of the present invention is:

[0025] (1) Weigh 1.2g of phosphatidylcholine, 0.8g of phosphatidylserine, 5g of trehalose, 2.5g of calcium chloride, and 0.005g of human recombinant tissue factor protein, and prepare 100ml of a mixed solution with water, mix well, and use high pressure to uniformly Emulsify with a quality machine and extruder, operating pressure 600bar, temperature 10°C-20°C, high-pressure homogenization, add 200nm filter membrane to extrude, repeat 10 times, and form an emulsion, which is the human recombinant tissue factor emulsion. The average particle size of the lipid droplet particles is between 100-200 nanometers.

[0026] (2) Weigh 5,000 grams of carboxymethyl chitosan, add it to 25 liters of water, slowly add 100 ml of the emulsion in step 1, stir and mix well, and control the temperature at 15°C-20°C.

[0027](3) Drying: Pre-freeze the mi...

Embodiment 2

[0029] Embodiment 2: a kind of preparation method based on chitosan and tissue factor combined hemostatic material is:

[0030] (1) Weigh 2.1g of phosphatidylcholine, 0.9g of phosphatidylserine, 7.5g of trehalose, 3g of calcium chloride, 0.005g of human recombinant tissue factor protein, and prepare 100ml of mixed solution with water, mix well, and use high pressure to Add extruder to emulsify, homogenize under high pressure at temperature 10-20°C and pressure 600bar, extruder add 200nm filter membrane to extrude, repeat 10 times to form emulsion, which is human recombinant tissue factor emulsion. The average particle size of lipid droplet particles is about 155 nanometers.

[0031] (2) Weigh 5,000 grams of carboxymethyl chitosan, add it to 25 liters of water, slowly add 100 ml of the emulsion in step 1, stir and mix well, and control the temperature at 15°C-20°C.

[0032] (3) Drying: pre-freeze the mixture in step 2 at -80°C for 10 hours, then put it into a freeze-drying box...

Embodiment 3

[0034] Embodiment 3: a kind of preparation method based on chitosan and tissue factor combination hemostatic material is:

[0035] (1) Weigh 2.1g of phosphatidylcholine, 0.9g of phosphatidylserine, 7.5g of trehalose, 3g of calcium chloride, 0.01g of human recombinant tissue factor protein, and prepare 100ml of mixed solution with water, mix well, and use high pressure to Adding extruder to emulsification, high-pressure homogenization at operating temperature of 10-20°C and pressure of 650bar, extruding with 200nm filter membrane in extruder, repeated 8 times to form emulsion, which is human recombinant tissue factor emulsification liquid. The average particle size of the lipid droplet particles is between 100-200 nanometers.

[0036] (2) Weigh 5,000 grams of carboxymethyl chitosan, add it to 25 liters of water, slowly add 100 ml of the emulsion in step 1, stir and mix well, and control the temperature at 15°C-20°C.

[0037] (3) Drying: pre-freeze the mixture in step 2 at -80...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
particle diameteraaaaaaaaaa
diameteraaaaaaaaaa
particle sizeaaaaaaaaaa
Login to View More

Abstract

A hemostatic material based on combination of chitosan and a tissue factor, and a preparation method thereof aim to realize short hemostasis time and good hemostasis effects. The hemostatic materialsare mainly prepared from the following components of a formula in parts by mass: 100 parts of the chitosan, 0.1-0.2 milli part of the human recombinant tissue factor, 0.04-0.06 part of phospholipid, 0.1-0.2 part of trehalose and 0.04-0.08 part of CaCl2. The preparation method comprises: preparing an emulsion by high-pressure treatment of the human recombinant tissue factor and the phospholipid, and then preparing a mixture of carboxymethyl chitosan and the human recombinant factor in ways of adding 0.02 ml of the emulsion in each gram of the carboxymethyl chitosan; performing vacuum freezing and drying after pre-freezing of 5-10 h at -40 to -80 DEG C; and grinding and sieving the mixture by a 100-mesh sieve into powder at an environmental temperature of 15-20 DEG C and the humidity of 30%,so as to obtain the external-use quick hemostatic material.

Description

technical field [0001] The invention relates to a hemostatic composition, which is a rapid hemostatic material for external use. Background technique [0002] Blood is a kind of red opaque viscous liquid flowing in human blood vessels and heart. It has the physiological functions of transportation, defense and regulation of osmotic pressure, acid-base balance and body temperature, and is an important substance for maintaining life. The total blood volume of adults accounts for about 8% of the body weight, which is about 4000-5000 ml. When traumatic bleeding occurs and blood vessels rupture, more than 1 / 3 of the total blood volume will be lost in a short period of time, and the face will appear pale and appear. Cold sweat, drop in blood pressure, weak pulse, etc., and even shock, leading to death. Therefore, rapid hemostasis and coagulation are the guarantee of blood supply to important organs such as the heart, brain, and kidneys, and the guarantee of life. All kinds of tr...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61L24/08A61L24/10A61L24/00A61L26/00A61L15/44A61L15/28A61L15/42A61L15/20
CPCA61L24/0015A61L24/08A61L24/108A61L26/0023A61L26/0047A61L26/0066A61L15/28A61L15/20A61L15/42A61L15/44A61L24/001A61L26/0061A61L2300/418A61L2300/236C08L5/08
Inventor 苗军光赵峰梅赵邑李红霞
Owner BEIJING REDCUBE MEDICAL EQUIP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com